Patents by Inventor John Mehnert

John Mehnert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7214673
    Abstract: Described herein are antipyschotic compounds of formula (I) wherein, A is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; Alk is (C1-4) alkylene optionally substituted with OH, methoxy, ethoxy, or F; Ar is optionally substituted phenyl, naphthyl, monocyclic heteroaromatic, or bicyclic heteroaromatic; R1 is hydrogen or (C1-4) alkyl optionally substituted with OH, OR3, or OCH2CH2OH, wherein R3 is (C1-2) alkyl; R2 is H, (C1-6) alkyl, halogen, fluorinated (C1-6) alkyl, OR4, SR4, NO2, CN, COR4, CONR5R6, SO2NR5R6, NR5R6, NR5COR4, NR5SO2R4, or optionally substituted phenyl, wherein R4 is hydrogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, or optionally substituted phenyl, R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionally substituted phenyl; Z is one or two substituents independently selected from hydrogen, halogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, OR7, SR7, NO2, CN, COR7, CONR8R9, SO2NR8R9, NR8SO2R
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: May 8, 2007
    Assignee: Eli Lilly and Company
    Inventors: Thomas Daniel Aicher, Zhaogen Chen, Joseph Herman Krushinski, Jr., Yvan Le Huerou, Marta Maria Pineiro-Nunez, Kevin Michael Ruley, John Mehnert Schaus, Dennis Charles Thompson, David Edward Tupper, Ying Chen, Margaret Mary Faul, Vincent Patrick Rocco
  • Patent number: 7157488
    Abstract: The present invention provides compounds of formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HT6 receptor. The present invention further provides a method of treating disorders associated with 5-HT6 receptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: January 2, 2007
    Assignee: Eli Lilly and Company
    Inventors: Zhaogen Chen, Michael Philip Cohen, Matthew Joseph Fisher, Bruno Giethlen, James Ronald Gillig, Jefferson Ray McCowan, Shawn Christopher Miller, John Mehnert Schaus
  • Publication number: 20050252928
    Abstract: An actuator assembly is disclosed which can dispense chemicals, such as insect control ingredients, from an aerosol container. The actuator assembly is mountable to the aerosol container and includes a solid plug that, upon initial activation, will be caused by the pressure of the chemical in the aerosol container to move to an unsealed position. Movement of the plug is retarded by a frictional engagement of the plug with an associated passage/conduit. The device can be manually activated, but is designed so that thereafter it does not need to be manually held open. The consumer has time to leave the room before spraying begins, and does not need to be present in the room before spraying has finished.
    Type: Application
    Filed: May 14, 2004
    Publication date: November 17, 2005
    Inventors: Brian Healy, Nathan Westphal, John Mehnert
  • Patent number: 6864262
    Abstract: The present invention provides a compound of the formula (I) and the pharmaceutically acceptable salts and solvates thereof, which is useful for treating bladder over-activity or urinary incontinence.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: March 8, 2005
    Assignee: Eli Lilly and Company
    Inventors: John Mehnert Schaus, Dennis Charles Thompson, Karl Bruce Thor
  • Patent number: 6777428
    Abstract: The present invention relates to a compound of formula I and a process for making: or a pharmaceutical acid addition salt thereof; which are useful for activating 5-HT1F receptors and inhibiting neuronal protein extravasation in a mammal.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: August 17, 2004
    Assignee: Eli Lilly and Company
    Inventors: Joseph Herman Krushinski, Jr., Vincent Mancuso, Freddy Andre Napora, John Mehnert Schaus
  • Publication number: 20040132800
    Abstract: The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.
    Type: Application
    Filed: February 27, 2004
    Publication date: July 8, 2004
    Inventors: Zhaogen Chen, Michael Philip Cohen, Matthew Joseph Fisher, Bruno Giethlen, James Ronald Gillig, Jefferson Ray McCowan, Shawn Christopher Miller, John Mehnert Schaus
  • Publication number: 20040110748
    Abstract: The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: September 18, 2003
    Publication date: June 10, 2004
    Inventors: Lisa Selsam Beavers, Robert Alan Gadski, Philip Arthur Hipskind, Craig William Lindsley, Karen Lynn Lobb, James Arthur Nixon, Richard Todd Pickard, John Mehnert Schaus, Takako Takakuwa, Brian Morgan Watson
  • Publication number: 20040102481
    Abstract: The present invention relates to compounds of formula I: which are antagonists of 5-HT6 receptor.
    Type: Application
    Filed: July 22, 2003
    Publication date: May 27, 2004
    Inventors: Sandra Ann Filla, Michael Edward Flaugh, James Ronald Gillig, Lawrence Joseph Heinz, Joseph Herman Krushinski, Bin Liu, Marta Maria Pineiro-Nunez, John Mehnert Schaus, John Stanley Ward
  • Publication number: 20040067962
    Abstract: The present invention provides a compound of the formula (I), and the pharmaceutically acceptable salts and solvates thereof, which is useful for treating bladder over-activity or urinary incontinence.
    Type: Application
    Filed: May 21, 2003
    Publication date: April 8, 2004
    Inventors: John Mehnert Schaus, Dennis Charles Thompson, Karl Bruce Thor
  • Patent number: 6608079
    Abstract: The present invention relates to a compound of formula (I), or a pharmaceutical acid addition salt thereof, which are useful for activating 5-HT1F receptors and inhibiting neuronal protein extravasation in a mammal.
    Type: Grant
    Filed: June 5, 2001
    Date of Patent: August 19, 2003
    Assignee: Eli Lilly and Company
    Inventors: John Mehnert Schaus, Yao-Chang Xu
  • Patent number: 6133290
    Abstract: The present invention relates to a compound of formula I: ##STR1## or a pharmaceutical acid addition salt thereof; which are useful for activating 5-HT.sub.1F receptors and inhibiting neuronal protein extravasation in a mammal.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: October 17, 2000
    Assignee: Eli Lilly and Company
    Inventors: Joseph Herman Krushinski, Jr., John Mehnert Schaus
  • Patent number: 5998622
    Abstract: This invention provides 5-HT.sub.1F agonists of Formula I; ##STR1## where A-B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.
    Type: Grant
    Filed: July 9, 1998
    Date of Patent: December 7, 1999
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Kirk W. Johnson, Lee A. Phebus, John Mehnert Schaus
  • Patent number: 5962474
    Abstract: This invention provides novel 5-HT.sub.1F agonists of Formula I ##STR1## where A--B, R,R.sup.1 and X are as defined in the specification, which are useful for the treatment of migraine and associated disorders.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: October 5, 1999
    Assignee: Eli Lilly and Company
    Inventors: James Edmund Audia, Bruce Anthony Dressman, James Joseph Droste, James Erwin Fritz, Stephen Warren Kaldor, Daniel James Koch, Joseph Herman Krushinski, Jr., Jeffrey Scott Nissen, Vincent Patrick Rocco, John Mehnert Schaus, Dennis Charles Thompson
  • Patent number: 5919936
    Abstract: This invention provides 5-HT.sub.1F agonists of Formula I: ##STR1## where A-B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.
    Type: Grant
    Filed: July 9, 1998
    Date of Patent: July 6, 1999
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Kirk W. Johnson, Lee A. Phebus, John Mehnert Schaus
  • Patent number: 5874427
    Abstract: This invention provides novel 5-HT.sub.1F agonists of the Formula ##STR1## in which X, Y, E, R, A, B, and n are as defined in the specification, which are useful for the treatment of migraine and associated disorders.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: February 23, 1999
    Assignee: Eli Lilly and Company
    Inventors: Sandra A. Filla, Joseph H. Krushinski, Jr., John Mehnert Schaus
  • Patent number: 5817671
    Abstract: This invention provides 5-HT.sub.1F agonists of Formula I: ##STR1## where A--B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: October 6, 1998
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Kirk W. Johnson, Lee A. Phebus, John Mehnert Schaus
  • Patent number: 5708008
    Abstract: This invention provides novel 5-HT.sub.1F agonists of Formula I ##STR1## where A--B, R, R.sup.1 and X are as defined in the specification, which are useful for the treatment of migraine and associated disorders.
    Type: Grant
    Filed: March 20, 1996
    Date of Patent: January 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: James Edmund Audia, Bruce Anthony Dressman, James Joseph Droste, James Erwin Fritz, Stephen Warren Kaldor, Daniel James Koch, Joseph Herman Krushinski, Jr., Jeffrey Scott Nissen, Vincent Patrick Rocco, John Mehnert Schaus, Dennis Charles Thompson